# SANGAMO THERAPEUTICS, INC. (SGMOQ) · Edgar & Edgarette company card

> Sangamo Therapeutics (SGMOQ) saw revenue fall 31.6% in FY2025 to $40 million, operating margin -307% against a -15.8% median for biological products, (no diagnostic substances), equity -23.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1001233 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SGMOQ) · [JSON](https://www.pops4.com/boards/company/SGMOQ.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $40M |
| Revenue growth, 1 year | -31.6% |
| Revenue growth per year | -22.7% |
| Operating margin | -306.5% (prior year -179.9%) |
| Net margin | -310.8% |
| Operating cash flow | −$97M |
| Capital spending | $102,000 |
| Free cash flow | −$97M |
| Cash | $21M |
| Long-term debt | — |
| Total assets | $60M |
| Total equity | −$14M |
| Equity ÷ assets | -23.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -103.36 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed bankruptcy or receivership, late quarterly report notice, auditor change, restructuring or exit costs in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -306.5% in FY2025; revenue is hard to predict: its 80% range is ±72%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $39.6M (FY2025). Experience: revenue down 31.6% on the year, down 22.7% a year over 4 years; operating margin -306.5%, down from -179.9%. Soundness: equity -23.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $10.9M and $67.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $9.6M to $76.9M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -306.5% against a -15.8% median; growth -31.6% against 21.4%.

Range logged 2026-09-24, receipt d0b0a6dc053cb19e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 1.03 Bankruptcy or receivership: 5, latest 2026-09-21 ([filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/0001193125-26-396644-index.htm))
- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-07-20 ([filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526309012/0001193125-26-309012-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-08-17 ([filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526354282/0001193125-26-354282-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-07-01 ([filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526292501/0001193125-26-292501-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2026-06-23 ([filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/0001193125-26-278582-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-02-03 ([filing](https://www.sec.gov/Archives/edgar/data/1001233/000100123326000002/0001001233-26-000002-index.htm))

## Recent filings

- 8-K · filed 2026-10-27 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526434171/0001193125-26-434171-index.htm)
- 8-K · filed 2026-10-16 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526423054/0001193125-26-423054-index.htm)
- 8-K · filed 2026-09-21 · 1.03 Bankruptcy or Receivership; 2.01 Completion of Acquisition or Disposition of Assets; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/0001193125-26-396644-index.htm)
- 8-K · filed 2026-09-08 · 1.03 Bankruptcy or Receivership; 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/0001104659-26-105905-index.htm)
- 8-K · filed 2026-08-28 · 1.01 Entry into a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/0001193125-26-374328-index.htm)
- 8-K · filed 2026-08-13 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/0001193125-26-347524-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001001233.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1001233

## Cite

POPS4, Edgar & Edgarette: SANGAMO THERAPEUTICS, INC. (SGMOQ) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/SGMOQ. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.